Navigation Links
Drug-Coated Balloons Slowly Making Their Mark on the European Interventional Cardiology Market
Date:11/3/2010

TORONTO, Nov. 3, 2010 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe. This market will continue to grow as physicians increasingly use the technology in cases where other devices may not be suitable.

Although drug-coated balloons lack extensive clinical data comparing their efficacy against other technologies, such as drug-eluting stents, they are being employed in patients where drug-eluting stents cannot be used. For example, patients who are not candidates for dual anti-platelet therapy are prevented from receiving a drug-eluting stent; in these patients a drug-coated balloon may be a viable treatment option. There is potential to use drug-coated balloons in combination with bare-metal stents to lower the risk of late stent thrombosis, which some believe is caused by the polymers holding the drug onto the stent platform. This way the patient would theoretically receive the benefits of the drug and the stent without the increased risk of late stent thrombosis.  

Drug-coated balloons are also being used to treat side branches of bifurcated lesions in the coronary arteries and for the treatment of instent restenosis. Although the practice of treating instent restenosis with another stent is currently being examined in clinical trials, physicians generally prefer not to perform this type of procedure.

"Although drug-coated balloons have been available in Europe as of 2007, they have experienced only minimal adoption so far," says Adrienne Ma, M.Sc., Analyst at MRG. "According to physicians interviewed by MRG, it is unlikely that interventional cardiologists will choose angioplasty alone when a stent could be placed. This market will continue to grow as the technology is used to treat patients in which other devices are not well suited. Physicians in Europe will continue to monitor data from clinical trials such as Eurocor's Valentines trial, Lutonix's PERVIDEO I trial, and B. Braun's PEPCAD trials, and positive results will further drive adoption."

MRG's European Markets for Interventional Cardiology Devices 2011 report includes analysis on France, Germany, Italy, and the UK. This report provides critical insight into trends that will fuel market growth for coronary stents, percutaneous transluminal coronary angioplasty balloon catheters, intravascular imaging catheters, pressure guidewires, optical coherence tomography, and accessory devices through 2015.  

About Millennium Research GroupMillennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com ), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Amy KrohnMillennium Research Group416-364-7776 ext. 101Chris Comfort
Decision Resources, Inc.
781-993-2597
'/>"/>

SOURCE Millennium Research Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents
2. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
3. STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children
4. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
5. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
6. Study Confirms: Your Hidden Food Allergies Are Making You Fat
7. Texas Childrens Hospital Discharges History-Making Teen Patient Again; This Time With a Transplanted Heart Replacing Mechanical Device
8. Teva Admits to Making False Statements in US Gianvi™ Label and Agrees to Corrective Measures
9. FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making
10. As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage
11. FDA Warns Three Companies to Stop Making Unproven Claims on Mouth Rinses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... 2016 Frontier Pharma: Chronic Obstructive Pulmonary ... Chronic Obstructive Pulmonary Disease (COPD) ... of the airways and lungs. Persistent breathing difficulties ... disease one of the leading causes of morbidity ... world. COPD is linked to cumulative exposure to ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... US Sports ... Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is ... just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends ... water may be safer than regular municipal or well water. The recent experience with ... Sharon Kleyne, could go a long way toward increasing public acceptance of recycled waste ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a ... KLAS: Software & Services for HIT Implementation Support & Staffing report with an ... vendor performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
Breaking Medicine News(10 mins):